» Articles » PMID: 23934233

Apolipoprotein E Gene Polymorphism Influences Aggressive Behavior in Prostate Cancer Cells by Deregulating Cholesterol Homeostasis

Overview
Journal Int J Oncol
Specialty Oncology
Date 2013 Aug 13
PMID 23934233
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

High circulating cholesterol and its deregulated homeostasis may facilitate prostate cancer progression. Genetic polymorphism in Apolipoprotein (Apo) E, a key cholesterol regulatory protein may effect changes in systemic cholesterol levels. In this investigation, we determined whether variants of the Apo E gene can trigger defective intracellular cholesterol efflux, which could promote aggressive prostate cancer. ApoE genotypes of weakly (non-aggressive), moderate and highly tumorigenic (aggressive) prostate cancer cell lines were characterized, and we explored whether the ApoE variants were associated with tumor aggressiveness generated by intra-cellular cholesterol imbalance, using the expression of caveolin-1 (cav-1), a pro-malignancy surrogate of cholesterol overload. Restriction isotyping of ApoE isoforms revealed that the non-aggressive cell lines carried ApoE ε3/ε3 or ε3/ε4 alleles, while the aggressive cell lines carried the Apoε2/ε4 alleles. Our data suggest a contrast between the non-aggressive and the aggressive prostate cancer cell lines in the pattern of cholesterol efflux and cav-1 expression. Our exploratory results suggest a relationship between prostate aggressiveness, ApoE isoforms and cholesterol imbalance. Further investigation of this relationship may elucidate the molecular basis for considering cholesterol as a risk factor of aggressive prostate tumors, and underscore the potential of the dysfunctional ApoE2/E4 isoform as a biomarker of aggressive disease.

Citing Articles

Exploration of vitamin D metabolic activity-related biological effects and corresponding therapeutic targets in prostate cancer.

Ding L, Wang Y, Tang Z, Ni C, Zhang Q, Zhai Q Nutr Metab (Lond). 2024; 21(1):17.

PMID: 38566155 PMC: 10988890. DOI: 10.1186/s12986-024-00791-2.


Gastrointestinal Dysfunction in Neurological and Neurodegenerative Disorders.

Raber J, Sharpton T Semin Neurol. 2023; 43(4):634-644.

PMID: 37607587 PMC: 10953489. DOI: 10.1055/s-0043-1771459.


A Novel Four Mitochondrial Respiration-Related Signature for Predicting Biochemical Recurrence of Prostate Cancer.

Xia Z, Liu H, Fan S, Tu H, Jiang Y, Wang H J Clin Med. 2023; 12(2).

PMID: 36675580 PMC: 9866444. DOI: 10.3390/jcm12020654.


Apolipoproteins: New players in cancers.

He Y, Chen J, Ma Y, Chen H Front Pharmacol. 2022; 13:1051280.

PMID: 36506554 PMC: 9732396. DOI: 10.3389/fphar.2022.1051280.


Association of fall rate and functional status by genotype in cancer survivors after exercise intervention.

McGinnis G, Holden S, Yu B, Ransom C, Guidarelli C, De B Oncotarget. 2022; 13:1259-1270.

PMID: 36441715 PMC: 11623406. DOI: 10.18632/oncotarget.28310.


References
1.
Hixson J, Vernier D . Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990; 31(3):545-8. View

2.
Sakr W . Prostatic intraepithelial neoplasia: A marker for high-risk groups and a potential target for chemoprevention. Eur Urol. 1999; 35(5-6):474-8. DOI: 10.1159/000019882. View

3.
Mahley R, Rall Jr S . Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2001; 1:507-37. DOI: 10.1146/annurev.genom.1.1.507. View

4.
Mahley R . Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240(4852):622-30. DOI: 10.1126/science.3283935. View

5.
Karasinska J, Hayden M . Cholesterol metabolism in Huntington disease. Nat Rev Neurol. 2011; 7(10):561-72. DOI: 10.1038/nrneurol.2011.132. View